Have malignancy rates increased in thyroidectomy cases
Göster/ Aç
Erişim
info:eu-repo/semantics/openAccessTarih
27 mart 20Yazar
KANAT, Burhan HakanÇay, Ferhat
Kutluer, Nizamettin
Aksoy, Nurullah
BOZAN, Mehmet Buğra
Arslan Solmaz, Özgen
KARACA KARAGÖZ, Zühal
İrtegün, Sinan
Aydın, Yusuf
Üst veri
Tüm öğe kaydını gösterKünye
Kanat, B. H., Çay, F., Kutluer, N., Aksoy, N., Bozan, M. B., Solmaz, Ö. A., ... & Aydın, Y. (2021). Have malignancy rates increased in thyroidectomy cases?. Archives of Medical Science-Civilization Diseases, 6(1), 46-49.Özet
ntroduction: This study aims to review thyroidectomy cases performed by
a single surgeon in a single centre during the course of 1 year, to determine
if the malignancy rate increased, and to compare the results with the liter ature.
Material and methods: We retrospectively evaluated data of patients who
underwent thyroidectomy between August 2018 and August 2019 in the
General Surgery Clinic of our hospital. The malignancy rate was calculated
and analysed according to the demographic data of the patients (gender
and age), preoperative thyroid nodule sizes, and postoperative pathological
mass sizes. Also, age, preoperative nodule size, and tumour size were all
evaluated according to gender.
Results: There were a total of 60 patients (14 (23%) male and 46 (77%) fe male). The pathology result revealed 16 (26.7%) malignant and 44 (73.3%)
benign biopsies. The mean age was 46.72 ±12.08 years (20–74). We found
that age, preoperative nodule size (cm), pathological tumour size (cm), and
thyroid function tests were not significantly associated with malignancy.
However, when age, preoperative nodule size, and tumour sizes were evalu ated according to gender, it was found that tumour sizes were significantly
larger in men than in women (p < 0.001). In addition, the mean age of male
patients was higher than that of women (p = 0.025).
Conclusions: The malignancy rate has increased in the thyroidectomies per formed in our centre. This finding is consistent with relevant studies from
the last 30 years. Therefore, it is likely that clinicians will continue to handle
an increased number of thyroid malignancies